Andrew David Berti Pharm.D.

Andrew David Berti Pharm.D.

Title

Assistant Professor

Department

Pharmacy Practice

Office Location

EACPHS, Room 4122

Phone

313-577-3565

Email

andrew.berti@wayne.edu

Andrew David Berti Pharm.D.

Degrees and Certifications

  • 2016 - Postdoctoral Fellowship, Antistaphylococcal Pharmacotherapy - University of Wisconsin-Madison
  • 2014 - Pharm.D. - University of Wisconsin-Madison, Madison WI
  • 2009 - Ph.D. Bacteriology - University of Wisconsin-Madison, Madison WI
  • 2003 - B.S. Microbiology - University of Rochester, Rochester NY

Positions and Employment

  • 2017-Present - Assistant Professor of Pharmacy Practice, Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI
  • 2016-2017 - Infectious Diseases Research Scientist, University of Wisconsin-Madison, Madison, WI
  • 2014-2016 - Postdoctoral Research Fellow (Dr. Warren E. Rose), University of Wisconsin-Madison
  • 2010-2014 - Research Associate (Dr. Warren E. Rose), University of Wisconsin-Madison, Madison, WI
  • 2009-2010 - Quality Assurance Analyst, EPIC Systems Corporation, Verona, WI
  • 2003-2009 - Graduate Research Assistant (Dr. Michael G. Thomas), University of Wisconsin-Madison
  • 1999-2003 - Undergraduate Research Assistant (Dr. J. Scott Butler), University of Rochester, NY

Awards and Honors

  • 2019-2020 - Eugene Applebaum College of Pharmacy Faculty Research Award
  • 2018-2019 - Eugene Applebaum College of Pharmacy Faculty Research Award
  • 2018 - EACPHS Faculty Research Award (Individual)
  • 2016 - ASM Microbe Travel Award
  • 2014 - Zeeh Pharmaceutical Experiment Station Director’s Award in Science and Technology
  • 2014 - ICAAC Infectious Disease Fellow
  • 2013 - AACP Walmart Scholar
  • 2008 - Jerome Stefaniak Fellow, UW-Madison, Microbiology Doctoral Training Program
  • 2002 - DeKiewiet Fellow, University of Rochester

Professional Memberships

  • 2017 - European Society of Clinical Microbiology and Infectious Diseases
  • 2017 - Infectious Diseases Society of America
  • 2017 - American Association of Colleges of Pharmacy
  • 2012 - Society of Infectious Diseases Pharmacists
  • 2010 - Wisconsin Society of Pharmacy Students
  • 2010 - American Pharmacists Association
  • 2005 - American Society for Microbiology

Areas of Expertise

  • Antimicrobial Pharmacotherapy
  • Bacterial Metabolism
  • Secondary Metabolism/Metabolic Engineering
  • Molecular Biology
  • Recombinant Genetics
  • Enzymology
  • Pharmacokinetics/Pharmacodynamics
  • Mechanisms of Antimicrobial Resistance
  • Antimicrobial Tolerance

Primary Research Interest

The Berti Lab investigates how combining antibiotics in a deliberate and rational manner can improve outcomes for patients with challenging bacterial infections. We integrate pharmacokinetics, bacteriology, molecular biology, metabolism and recombinant genetics to examine when combination therapy is appropriate, why combination therapy can provide benefit and how best to administer antibiotic combinations.

RESEARCH OPPORTUNITIES ARE AVAILABLE FOR STUDENTS AND TRAINEES INTERESTED IN BACTERIAL METABOLISM AS WELL AS ANTI-INFECTIVES RESEARCH.

  • Combination Antimicrobial Therapy
  • Mechanisms of Antimicrobial Resistance
  • Mechanisms of Antimicrobial Tolerance
  • Optimization of Pharmacological Interventions
  • Staphylococcus aureus

Recent Publications

  • Berti AD and Rose WE. Optimal Use of Beta-lactam Antibiotics. In: Mylonakis E, ed. Antimicrobial Stewardship: Principles and Practice. Wallingford, England: CABI; 2016.

  • Berti AD, Shukla N, Rottier AD, McCrone JS, Turner HM, Monk IR, Baines SL, Howden BP, Proctor RA, Rose WE (in press). Daptomycin selects for genetic and phenotypic adaptations leading to antibiotic tolerance in methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2018;73(8):2030-2033.
  • Ritscher AM, Ranum N, Malak JD, Ahrabi-Fard S, Baird J, Berti AD, Curtis W, Holden M, Jones CD, Kind J, Kinsey W, Koepke R, Schauer SL, Stein E, VanOrman S, Ward BG, Zahner SJ, Hayney MS. Meningococcal serogroup B outbreak response at a large public university. J Am Coll Health. 2018;66(3):1-6
  • Fernandez-Llimos F, Berti AD, Yeung D et al. Scholarly publishing depends on peer reviewers. Pharm Pract. 2018;16(1):1236.
  • Zheng X, Berti AD, McCrone S, Roch M, Rosato AE, Rose WE, Chen B. Combination antibiotic exposure selectively alters the development of vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2018;62(2):e02100-17.
  • Berti AD, Schroeder JW, Rottier AD, McCrone JS, Wang J, Rose WE. Evolution of antibiotic tolerance during oxacillin, daptomycin and dalbavancin therapy results in breakthrough Staphylococcus aureus bacteremias. Open Forum Infect Dis. 2017;4(S1):S4.
  • Rose WE, Shukla SK, Berti AD, Hayney MS, Henriquez KM, Ranzoni A, Cooper MA, Proctor RA, Nizet V, Sakoulas G. Increased endovascular Staphylococcus aureus inoculum is the link between elevated serum interleukin 10 concentrations and mortality in patients with bacteremia. Clin Infect Dis. 2017;64(10):1406-1412.
  • Berti AD, Theisen E, Sauer JD, Nonejuie P, Olson J, Pogliano J, Sakoulas G, Nizet V, Proctor RA, Rose WE. Penicillin binding protein 1 is important in the compensatory response of Staphylococcus aureus to daptomycin-induced membrane damage and is a potential target for β-lactam-daptomycin synergy. Antimicrob Agents Chemother. 2015;60(1):451-458.
  • Berti AD, Baines SL, Howden BP, Sakoulas G, Nizet V, Proctor RA, Rose WE. Heterogeneity of genetic pathways toward daptomycin nonsusceptibility in Staphylococcus aureusdetermined by adjunctive antibiotics. Antimicrob Agents Chemother. 2015;59(5):2799-2806.
  • Berti AD, Hutson PR, Schulz LT, Webb AP, Rose WE. Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion. Am J Health Sys Pharm. 2015;72(5):390-395.
  • Berti AD, Sakoulas G, Nizet V, Tewhey R, Rose WE. β-lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2013;57(10):5005-5012.
  • Rose WE, Berti AD, Hatch JB, Maki DG. Relationship of in vitro synergy and treatment outcome with daptomycin plus rifampin in patients with invasive methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother. 2013;57(7):3450-3452.